Invesco’s Tevogen Bio Holdings TVGN Stock Holding History

Invesco’s Portfolio TVGN Stock Details TVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-236	Closed	-$3.92K	–	3837
2025 Q4	$3.92K	Sell	236 -127	-35%	-$3.3K	﹤0.01%	3745
2025 Q3	$14.3K	Buy	363 +2	+0.6%	+$98	﹤0.01%	3781
2025 Q2	$22.6K	Buy	361 +5	+1%	+$285	﹤0.01%	3755
2025 Q1	$19.2K	Buy	356 +16	+5%	+$1.05K	﹤0.01%	3745
2024 Q4	$17.5K	Buy	340 +137	+67%	+$8.93K	﹤0.01%	3744
2024 Q3	$3.74K	Sell	203 -2	-1%	-$58	﹤0.01%	3751
2024 Q2	$7.43K	Buy	+205	New	+$13.4K	﹤0.01%	3866

Other funds holding TVGN

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Invesco's TVGN Position: Q1 2026 in Review

Invesco sold out of Tevogen Bio Holdings (TVGN) in Q1 2026, closing a stake of 236 shares — an estimated $3.92K sold.

Invesco first reported a position in TVGN in Q2 2024 and held it in 7 quarters. The position peaked at $22.6K in Q2 2025. 30 funds tracked by Wall St. Rank hold TVGN as of Q1 2026.

Invesco reported no remaining Tevogen Bio Holdings position as of Q1 2026 after selling out during the quarter.
Invesco sold 236 Tevogen Bio Holdings shares in Q1 2026, an estimated $3.92K.
Invesco first reported a position in Tevogen Bio Holdings in Q2 2024 and held it in 7 quarters.
Invesco's Tevogen Bio Holdings position peaked at $22.6K in Q2 2025.
30 funds tracked by Wall St. Rank held Tevogen Bio Holdings as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.